Plasma renin activity assessment guides antihypertensive therapy by distinguishing low-renin, volume-dependent hypertension (PRA < 0.65 ng/ml/h) from RAAS-activated hypertension (PRA > 0.65 ng/ml/h).
Does plasma renin activity assessment guide antihypertensive therapy choice in hypertension management?
Plasma renin activity assessment may help tailor antihypertensive therapy by distinguishing between volume-dependent and RAAS-driven hypertension.
The recent interest to plasma renin activity (PRA) is due to the opportunity of antihypertensive therapy choice that is based on the understanding of the interrelation between renin-angiotensin-aldosterone system (RAAS) and mechanisms of water balance mediated by the renal sodium absorption and water retention. PRA is the way to understand the primary mechanism of blood pressure elevation. PRA < 0,65 ng/ml/h indicates the water retention, and hypertension is considered low-renin and «volume-dependent». If PRA is more than 0,65 ng/ml/h hypertension results from excessive renin secretion and RAAS activation.
Kotovskaya et al. (Mon,) conducted a review in Hypertension. Plasma renin activity (PRA) assessment was evaluated. Plasma renin activity assessment guides antihypertensive therapy by distinguishing low-renin, volume-dependent hypertension (PRA < 0.65 ng/ml/h) from RAAS-activated hypertension (PRA > 0.65 ng/ml/h).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: